Vitrolife AB (publ) (VITR.ST)
SEK 149.6
(3.53%)
SEK 149.6
(3.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.85 Billion SEK | -1077.41% |
| 2022 | 394 Million SEK | 15.54% |
| 2021 | 341 Million SEK | 18.88% |
| 2020 | 286.84 Million SEK | -25.06% |
| 2019 | 382.78 Million SEK | 23.6% |
| 2018 | 309.69 Million SEK | 17.47% |
| 2017 | 263.64 Million SEK | 38.49% |
| 2016 | 190.36 Million SEK | 4.11% |
| 2015 | 182.84 Million SEK | 67.58% |
| 2014 | 109.1 Million SEK | 93.89% |
| 2013 | 56.27 Million SEK | -83.14% |
| 2012 | 333.77 Million SEK | 999.38% |
| 2011 | 30.36 Million SEK | 4.04% |
| 2010 | 29.18 Million SEK | -14.46% |
| 2009 | 34.11 Million SEK | 13.73% |
| 2008 | 29.99 Million SEK | -16.81% |
| 2007 | 36.05 Million SEK | 137.23% |
| 2006 | 15.19 Million SEK | 2.29% |
| 2005 | 14.85 Million SEK | 24.49% |
| 2004 | 11.93 Million SEK | -73.29% |
| 2003 | 44.68 Million SEK | -61.65% |
| 2002 | 116.5 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 143 Million SEK | 24.35% |
| 2024 Q1 | 115 Million SEK | 102.75% |
| 2024 Q3 | 116 Million SEK | -18.88% |
| 2023 FY | -3.85 Billion SEK | -1077.41% |
| 2023 Q1 | 100 Million SEK | 35.14% |
| 2023 Q2 | 106 Million SEK | 6.0% |
| 2023 Q3 | 122 Million SEK | 15.09% |
| 2023 Q4 | -4.17 Billion SEK | -3525.41% |
| 2022 Q2 | 130 Million SEK | 58.54% |
| 2022 Q1 | 82 Million SEK | 151.36% |
| 2022 Q3 | 108 Million SEK | -16.92% |
| 2022 Q4 | 74 Million SEK | -31.48% |
| 2022 FY | 394 Million SEK | 15.54% |
| 2021 Q1 | 118 Million SEK | 10.05% |
| 2021 Q2 | 86 Million SEK | -27.12% |
| 2021 Q4 | 32.62 Million SEK | -68.63% |
| 2021 FY | 341 Million SEK | 18.88% |
| 2021 Q3 | 104 Million SEK | 20.93% |
| 2020 Q4 | 107.22 Million SEK | 21.62% |
| 2020 FY | 286.84 Million SEK | -25.06% |
| 2020 Q2 | 11.62 Million SEK | -85.44% |
| 2020 Q3 | 88.16 Million SEK | 658.39% |
| 2020 Q1 | 79.83 Million SEK | -16.95% |
| 2019 Q3 | 106.7 Million SEK | 12.75% |
| 2019 Q4 | 96.12 Million SEK | -9.91% |
| 2019 Q2 | 94.63 Million SEK | 10.92% |
| 2019 FY | 382.78 Million SEK | 23.6% |
| 2019 Q1 | 85.31 Million SEK | 1.57% |
| 2018 Q4 | 83.99 Million SEK | 11.9% |
| 2018 Q2 | 79.27 Million SEK | 11.09% |
| 2018 Q3 | 75.06 Million SEK | -5.3% |
| 2018 Q1 | 71.36 Million SEK | 4.36% |
| 2018 FY | 309.69 Million SEK | 17.47% |
| 2017 Q4 | 68.37 Million SEK | 5.59% |
| 2017 FY | 263.64 Million SEK | 38.49% |
| 2017 Q2 | 71.29 Million SEK | 20.43% |
| 2017 Q1 | 59.2 Million SEK | -0.52% |
| 2017 Q3 | 64.76 Million SEK | -9.17% |
| 2016 Q3 | 44.47 Million SEK | -7.27% |
| 2016 FY | 190.36 Million SEK | 4.11% |
| 2016 Q1 | 38.42 Million SEK | -32.8% |
| 2016 Q2 | 47.95 Million SEK | 24.8% |
| 2016 Q4 | 59.51 Million SEK | 33.83% |
| 2015 FY | 182.84 Million SEK | 67.58% |
| 2015 Q4 | 57.18 Million SEK | 9.28% |
| 2015 Q1 | 34.98 Million SEK | 23.08% |
| 2015 Q2 | 38.35 Million SEK | 9.62% |
| 2015 Q3 | 52.32 Million SEK | 36.42% |
| 2014 Q2 | 23.01 Million SEK | 3.76% |
| 2014 Q1 | 22.17 Million SEK | 44.43% |
| 2014 FY | 109.1 Million SEK | 93.89% |
| 2014 Q4 | 28.42 Million SEK | -19.91% |
| 2014 Q3 | 35.49 Million SEK | 54.24% |
| 2013 FY | 56.27 Million SEK | -83.14% |
| 2013 Q2 | 12.1 Million SEK | 1.94% |
| 2013 Q1 | 11.87 Million SEK | -96.08% |
| 2013 Q3 | 16.93 Million SEK | 39.87% |
| 2013 Q4 | 15.35 Million SEK | -9.32% |
| 2012 FY | 333.77 Million SEK | 999.38% |
| 2012 Q3 | 8.41 Million SEK | -36.13% |
| 2012 Q4 | 302.91 Million SEK | 3501.82% |
| 2012 Q1 | 9.28 Million SEK | 348.57% |
| 2012 Q2 | 13.16 Million SEK | 41.88% |
| 2011 Q1 | 8.78 Million SEK | 1136.72% |
| 2011 FY | 30.36 Million SEK | 4.04% |
| 2011 Q4 | 2.06 Million SEK | -78.46% |
| 2011 Q3 | 9.6 Million SEK | -2.98% |
| 2011 Q2 | 9.9 Million SEK | 12.77% |
| 2010 Q1 | 9.62 Million SEK | -13.05% |
| 2010 Q2 | 9.34 Million SEK | -2.92% |
| 2010 Q3 | 10.77 Million SEK | 15.35% |
| 2010 Q4 | -847 Thousand SEK | -107.86% |
| 2010 FY | 29.18 Million SEK | -14.46% |
| 2009 FY | 34.11 Million SEK | 13.73% |
| 2009 Q2 | 7.23 Million SEK | 0.0% |
| 2009 Q4 | 11.06 Million SEK | 52.44% |
| 2009 Q3 | 7.26 Million SEK | 0.32% |
| 2008 FY | 29.99 Million SEK | -16.81% |
| 2007 FY | 36.05 Million SEK | 137.23% |
| 2006 FY | 15.19 Million SEK | 2.29% |
| 2005 FY | 14.85 Million SEK | 24.49% |
| 2004 FY | 11.93 Million SEK | -73.29% |
| 2003 FY | 44.68 Million SEK | -61.65% |
| 2002 FY | 116.5 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | -4847.391% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 3820.773% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 3820.773% |
| Arcoma AB | 2.56 Million SEK | 150295.008% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | -2682.876% |
| BICO Group AB (publ) | -835.7 Million SEK | -360.811% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 15518.185% |
| CellaVision AB (publ) | 130.3 Million SEK | 3055.283% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | -4726.298% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -13094.377% |
| C-Rad AB (publ) | 35.52 Million SEK | 10939.033% |
| Duearity AB (publ) | -26.19 Million SEK | -14604.086% |
| Dignitana AB (publ) | -17.36 Million SEK | -22079.347% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -3962.236% |
| Getinge AB (publ) | 2.41 Billion SEK | 259.66% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -5565.127% |
| Iconovo AB (publ) | -45.89 Million SEK | -8291.106% |
| Integrum AB (publ) | 4.03 Million SEK | 95599.591% |
| Luxbright AB (publ) | -25.37 Million SEK | -15076.278% |
| Mentice AB (publ) | -2.81 Million SEK | -136605.715% |
| OssDsign AB (publ) | -130.49 Million SEK | -2851.116% |
| Paxman AB (publ) | 8.33 Million SEK | 46330.492% |
| Promimic AB (publ) | -9.22 Million SEK | -41658.838% |
| Qlife Holding AB (publ) | -159.95 Million SEK | -2307.537% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -6828.128% |
| ScandiDos AB (publ) | -14.64 Million SEK | -26192.073% |
| Sectra AB (publ) | 428.38 Million SEK | 998.951% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -6360.109% |
| Senzime AB (publ) | -134.14 Million SEK | -2770.689% |
| SpectraCure AB (publ) | -20.44 Million SEK | -18739.587% |
| Stille AB | 26.64 Million SEK | 14552.451% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 4294.075% |